Lindsey Murray, PhD, MPH, is Executive Director of the Rare Disease Clinical Outcome Assessment (COA) Consortium. Dr. Murray has more than 15 years of experience in health outcomes research. She specializes in quantifying the patient’s perspective of health, illness, and treatment through COA tool development, psychometric testing, and the design and analysis of clinical trials involving COAs. Prior to joining C-Path, Dr. Murray was an integral part of the EXacerbations of Chronic Pulmonary Disease Tool (EXACT®) – Patient-Reported Outcome Initiative team, taking over as Director of the EXACT PROgram. As Director, she had oversight of all EXACT licensing, translations, and analysis work being conducted on the EXACT and its derivative measure, the Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS®: COPD). Dr. Murray’s research activities also included serving as principal investigator to develop patient-reported outcome measures in several rare diseases, including neurotrophic keratosis and hypertrophic cardiomyopathy. She was also involved in adapting the E-RS: COPD for use in idiopathic pulmonary fibrosis (E-RS: IPF) and asthma-COPD overlap syndrome.
Dr. Murray holds a PhD from George Washington University in epidemiology. She received her MPH from George Washington University in epidemiology with a certificate in health promotion. Previously, Dr. Murray received a BA from the University of Virginia in Charlottesville, Virginia, where she double majored in anthropology and biology with a minor in German literature and language studies.